Search research articles
Contact Us
Filters
Showing results (171-180 of 206) with videos related to
Page
of 21
Sort By:
Cancer Research
|
April 9, 2009
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR
Martin L Sos, Mirjam Koker, Barbara A Weir, et al.
International Journal of Cancer
|
March 8, 2023
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM
Thorsten O Goetze, Ralf-Dieter Hofheinz, Timo Gaiser, et al.
Nature Medicine
|
March 7, 2025
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial
Kohei Shitara, Yelena Y Janjigian, Jaffer Ajani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2014
MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung
Hans-Ulrich Schildhaus, Anne M Schultheis, Josef Rüschoff, et al.
The New England Journal of Medicine
|
December 9, 2025
Ianalumab plus Eltrombopag in Immune Thrombocytopenia
Adam Cuker, Thomas Stauch, Nichola Cooper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 23, 2011
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography
Thomas Zander, Matthias Scheffler, Lucia Nogova, et al.
Oncoimmunology
|
July 29, 2016
Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma
Hans A Schlößer, Uta Drebber, Michael Kloth, et al.
The New England Journal of Medicine
|
March 31, 2021
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J Kelly, Jaffer A Ajani, Jaroslaw Kuzdzal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
Yelena Y Janjigian, Jaffer A Ajani, Markus Moehler, et al.
Clinical Nutrition ESPEN
|
June 26, 2025
Individually compounded multi-chamber vs. standardized parenteral nutrition bags in solid tumors-A randomized clinical trial (IKF-010)
Thorsten Oliver Goetze, Ralf-Dieter Hofheinz, Ingeborg Roetzer, et al.
Page
of 21
Search research articles
Search
Showing results (171-180 of 206) with videos related to
Sort By:
Page
of 21
Cancer Research
|
April 9, 2009
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR
Martin L Sos, Mirjam Koker, Barbara A Weir, et al.
International Journal of Cancer
|
March 8, 2023
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM
Thorsten O Goetze, Ralf-Dieter Hofheinz, Timo Gaiser, et al.
Nature Medicine
|
March 7, 2025
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial
Kohei Shitara, Yelena Y Janjigian, Jaffer Ajani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2014
MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung
Hans-Ulrich Schildhaus, Anne M Schultheis, Josef Rüschoff, et al.
The New England Journal of Medicine
|
December 9, 2025
Ianalumab plus Eltrombopag in Immune Thrombocytopenia
Adam Cuker, Thomas Stauch, Nichola Cooper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 23, 2011
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography
Thomas Zander, Matthias Scheffler, Lucia Nogova, et al.
Oncoimmunology
|
July 29, 2016
Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma
Hans A Schlößer, Uta Drebber, Michael Kloth, et al.
The New England Journal of Medicine
|
March 31, 2021
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J Kelly, Jaffer A Ajani, Jaroslaw Kuzdzal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
Yelena Y Janjigian, Jaffer A Ajani, Markus Moehler, et al.
Clinical Nutrition ESPEN
|
June 26, 2025
Individually compounded multi-chamber vs. standardized parenteral nutrition bags in solid tumors-A randomized clinical trial (IKF-010)
Thorsten Oliver Goetze, Ralf-Dieter Hofheinz, Ingeborg Roetzer, et al.
Page
of 21